Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sung Yong Lee, MD
Korea University Guro Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Korea University Anam Hospital
Anam, South Korea
Recruiting - Hallym University Sacred Heart Hospital
Anyang, South Korea
Recruiting - Chonnam National University Hwasun Hospital
Hwasun, South Korea
Recruiting - Catholic University of Korea Eunpyeong St. Mary'S Hospital
Seoul, South Korea
Recruiting - Catholic University of Korea Yeouido St. Mary'S Hospital
Seoul, South Korea
Recruiting - Korea University Guro Hospital
Seoul, South Korea
Recruiting - Seoul Asan Hospital
Seoul, South Korea
Recruiting - Busan National University Hospital Yangsan
Yangsan, South Korea
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Aug 2023
- Primary completion
- 31 Aug 2026
- Completion
- 31 Dec 2026
- Last update posted
- 30 Aug 2023
- Registered enrollment
- 60
- Registry id
- NCT05841472
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.